Company profile
Outlook Therapeutics company profile
Outlook Therapeutics develops an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion. Their ophthalmic formulations also use in treating retinal diseases.
Business identity
- Contact email
- [email protected]
- Phone number
- +1 609 619 3990
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Revenue range
- $0-$1M
- Founded
- 2011-01-01, Year
Headquarters
- Headquarters
- Iselin, New Jersey, United States
- Postal code
- 08830
- Country code
- US
- Continent
- North America